Inocip-F5 Tablet SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 5 mg, indicated for the prophylactic management of migraine and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effect by reducing heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand. It is effective in preventing migraine attacks by modulating vascular tone and central nervous system activity. Flunarizine, a calcium channel blocker with antihistaminic properties, helps prevent migraine by inhibiting calcium influx into vascular smooth muscle cells and neurons, stabilizing vascular tone and reducing neuronal excitability. The sustained-release formulation ensures prolonged plasma concentration, enhancing patient compliance and minimizing dosing frequency. Inocip-F5 is particularly beneficial for patients requiring both cardiovascular control and migraine prophylaxis. It should be used under medical supervision, with caution in patients with asthma, bradycardia, hypotension, or severe hepatic impairment. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and mild sedation. Contraindications include hypersensitivity to either component, severe sinus bradycardia, and uncompensated heart failure. Regular monitoring of blood pressure and heart rate is recommended during therapy to optimize therapeutic outcomes and minimize risks.